Effective and sustainable biologic treatment of psoriasis: What can we learn from new clinical data?

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue SUPPL. 2, 2012, Pages 21-29

  Langley, R G ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BIOLOGICAL PRODUCT; BRIAKINUMAB; CALCIPOTRIOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; ETANERCEPT; ETRETINATE; INFLIXIMAB; METHOTREXATE; RETINOID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INFECTION; LONG TERM CARE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SKIN CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PSORIASIS; PUVA THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857570443     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04412.x     Document Type: Review

References (69)

1. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566. (Pubitemid 351239154)
2. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115. (Pubitemid 350298146)
3. Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163: 402-411.
4. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022. (Pubitemid 37448924)
5. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312. (Pubitemid 40933433)
6. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726. (Pubitemid 46955730)
7. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606. (Pubitemid 44436647)
8. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374. (Pubitemid 41443403)
9. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31e1-15.
10. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674. (Pubitemid 351671883)
11. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684. (Pubitemid 351671884)
12. Gubner R, August S, Ginsberg V,. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176-182.
13. Edmundson WF, Guy WB,. Treatment of psoriasis with folic acid antagonists. AMA Arch Derm 1958; 78: 200-203.
14. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB,. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 6: 46-51. (Pubitemid 12197905)
15. Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA,. Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 7: 758-762. (Pubitemid 13242271)
16. Armstrong RB, Poh-Fitzpatrick MB,. Methotrexate and ultraviolet radiation. Arch Dermatol 1982; 118: 177-178. (Pubitemid 12185311)
17. Vanderveen EE, Ellis CN, Campbell JP, Case PC, Voorhees JJ,. Methotrexate and etretinate as concurrent therapies in severe psoriasis. Arch Dermatol 1982; 118: 660-662. (Pubitemid 12061439)
18. Gollnick HP,. Oral retinoids-efficacy and toxicity in psoriasis. Br J Dermatol 1996; 135 (Suppl. 49): 6-17.
19. Horiguchi M, Takigawa M, Imamura S,. Treatment of generalized pustular psoriasis with methotrexate and colchicine. Arch Dermatol 1981; 117: 760. (Pubitemid 12248787)
20. Clark CM, Kirby B, Morris AD, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999; 141: 279-282. (Pubitemid 29397996)
21. Aydin F, Canturk T, Senturk N, Turanli AY,. Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol 2006; 31: 520-524. (Pubitemid 43806583)
22. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-284.
23. Finzi AF, Ippolito F, Panconesi E, Giannotti B, Rebora A,. Cyclosporin therapy in psoriasis: recommendations for treatment. Italian Multicenter Study Group on Cyclosporin in Psoriasis. Dermatology 1993; 187 (Suppl. 1): 38-40. (Pubitemid 23223846)
24. Berth-Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Br J Dermatol 1997; 136: 527-530. (Pubitemid 27160325)
25. Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999; 141: 283-291. (Pubitemid 29397997)
26. Ho VC, Griffiths CE, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001; 44: 643-651. (Pubitemid 32249523)
27. Mueller W, Herrmann B,. Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555. (Pubitemid 9258270)
28. Geiger JM, Czametzki BM., Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica 1988; 176: 182-190.
29. Olsen EA, Weed WW, Meyer CJ, Cobo LM,. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681-686. (Pubitemid 19251725)
30. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ,. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 1988; 18: 655-662.
31. Lowe NJ, Lazarus V, Matt L,. Systemic retinoid therapy for psoriasis. J Am Acad Dermatol 1988; 19: 186-191.
32. Lassus A, Geiger JM, Nyblom M, Virrankoski T, Kaartamaa M, Ingervo L,. Treatment of severe psoriasis with etretin (RO 10-1670). Br J Dermatol 1987; 117: 333-341. (Pubitemid 17126010)
33. Lebwohl M, Drake L, Menter A, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001; 45: 544-553. (Pubitemid 32917249)
34. van de Kerkhof PC, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 1998; 138: 84-89. (Pubitemid 28077942)
35. Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC,. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1-125.
36. Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P,. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991; 25: 682-684.
37. Ruzicka T, Sommerburg C, Braun-Falco O, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 1990; 126: 482-486. (Pubitemid 20128961)
38. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R,. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991; 24: 591-594.
39. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
40. Feldman SR, Koo JY, Menter A, Bagel J,. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol 2005; 53: 101-107. (Pubitemid 40826702)
41. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A,. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009; 219: 209-218.
42. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-138. (Pubitemid 46835379)
43. Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365: 1586-1596.
44. Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-1117.
45. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35. (Pubitemid 43038667)
46. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632; discussion 1632. (Pubitemid 37523083)
47. van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177-1185.
48. Van Lumig PP, Lecluse LL, Driessen RJ, et al. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol 2010; 163: 838-846.
49. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH,. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2011; Jul 11. [Epub ahead of print].
50. Kimball AB, Bao Y, Yu AP, et al. Approved adalimumab dosing regimen associated with greater efficacy and lower cost per responder compared with 40-mg every other week dosing without initial 80-mg dose: analysis of outcomes from adalimumab psoriasis clinical trial database. J Eur Acad Dermatol Venereol 2011, Lisbon, Portugal; FC01.8. Available at
51. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB,. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847. (Pubitemid 32539117)
52. Clark L, Lebwohl M,. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008; 58: 443-446.
53. Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010; 63: 571-579.
54. Armstrong AW, Bao Y, Signorovitch J, Samuelson T, Sundaram M, Mulani PM,. Comparison of benefit-risk profiles with adalimumab versus etanercept treatment for moderate to severe psoriasis, stratified by weight. J Eur Acad Dermatol Venereol 2011, Lisbon, Portugal; FC03.1. Available at
55. Gottlieb A, Langley RG, Strober B, et al. Efficacy and safety of adding methotrexate to etanercept versus etanercept monotherapy in adults with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol 2011, Lisbon, Portugal; PO1085. Available at
56. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
57. Gisondi P, Del Giglio M, Cotena C, Girolomoni G,. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008; 158: 1345-1349. (Pubitemid 351692891)
58. Smith EC, Riddle C, Menter MA, Lebwohl M,. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008; 47: 514-518. (Pubitemid 351560322)
59. Lina C, Conghua W, Nan L, Ping Z,. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol 2011; 31: 596-605.
60. Bejarano V, Conaghan PG, Quinn MA, Saleem B, Emery P,. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology (Oxford) 2010; 49: 1971-1974.
61. Daly M, Alikhan A, Armstrong AW,. Combination systemic therapies in psoriatic arthritis. J Dermatol Treat 2011; 22: 276-284.
62. Zachariae C, Mork NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008; 88: 495-501.
63. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W,. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-526.
64. Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM,. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010; 162: 1349-1358.
65. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-1869.
66. Kaandorp CJ, Van Schaardenburg D, Krijnen P, Habbema JD, van de Laar MA,. Risk factors for septic arthritis in patients with joint disease. A prospective study. Arthritis Rheum 1995; 38: 1819-1825. (Pubitemid 26010283)
67. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE,. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-2293.
68. Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54: S92-S100. (Pubitemid 43243480)
69. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006; 54: S101-S111. (Pubitemid 43243481)